ft 09 mar 93 ici clear way zeneca issu settl us patent disput imperi chemic industri barr laboratori new york base gener group settl drug patent disput move help clear way ici wholli own subsidiari zeneca make pound 1 3bn right issu june ici barr reach court settlement conclud disput us patent nolvadex zeneca best sell breast cancer drug last april ici nolvadex patent invalid us southern district court new york decid irregular file us patent nolvadex made patent unenforc ici appeal court decis put nolvadex us annual sale dollar 265m pound 186m risk patent suppos run anoth nine year recent us patent expiri includ ici heart drug tenormin follow sale fall much 50 per cent 12 month gener manufactur undercut price previous patent brand two group agre dismiss claim rais action acknowledg substanti possibl drug us patent would held valid enforc drug us patent schedul expir 2002 expir countri agreement ici pay dollar 21m barr us group enter non exclus distributorship agreement zeneca start sell drug novemb 1 ici indic price medicin would sold barr would allow us compani undercut nolvadex exist price substanti ici announc last month spin zeneca pharmaceut agrochem special chemic subsidiari demerg need confirm may extraordinari gener meet barr also challeng wellcom uk group valid patent azt hiv treatment glaxo europ biggest drug group yesterday announc notifi uk medicin control agenc new inhal steroid asthma treatment fluticason given product licenc decis increas likelihood drug receiv licenc regulatori bodi